Table III.
Results of budget impact analysis.
| Scenario 1 | Year 1 | Year 2 | Year 3 | |
|---|---|---|---|---|
| Standard platelets | Share | 0.80 | 0.60 | 0.34 |
| Cost of adult doses | € 33,162,044 | € 24,871,533 | € 14,093,869 | |
| Intercept® platelets | Share | 0.10 | 0.20 | 0.33 |
| Cost of adult doses | € 6,383,693 | € 12,767,386 | € 21,066,187 | |
| NAIC | € 1,745,246 | € 3,490,492 | € 5,759,312 | |
| Mirasol® platelets | Share | 0.10 | 0.20 | 0.33 |
| Cost of adult doses | € 5,554,642 | € 11,109,284 | € 18,330,319 | |
| NAIC | € 1,518,591 | € 3,037,182 | € 5,011,350 | |
| Total | Total cost | € 48,364,216 | € 55,275,877 | € 64,261,037 |
| Scenario 2 | Year 1 | Year 2 | Year 3 | |
| Standard platelets | Share | 1.00 | 1.00 | 1.00 |
| Cost of adult doses | € 41,452,555 | € 41,452,555 | € 41,452,555 | |
| Scenarios 1 – 2 | Balance | € 6,911,661 | € 13,823,322 | € 22,808,482 |
Scenario 1: progressively increasing proportion of pathogen reduction technology platelets treated with the Intercept® and Mirasol® technologies, from 10% each in the first year up to 33% each in the third year; Scenario 2: use of standard platelets only.
NAIC: net annual increased cost.